Skip to main content
. 2008 Feb;4(1):225–233. doi: 10.2147/tcrm.s6862

Table 2.

Summary of randomized, double-blind, placebo controlled trials of PPI in LPR

Study No of patients Inclusion criteria Important exclusion criteria Medication Duration of treatment (wk) Outcome measure for symptoms Significant difference between PPI and placebo
Havas (1999) 15 Symptoms and laryngoscopic signs of LPR Pre-existing anti-secretory medication, severe oesophagitis at endoscopy Lansoprazole 30 mg bd 12 Significant reduction in mean composite symptom score No
Noordzij (2001) 30 Symptoms of LPR for min 3 months and abnormal result of hypopharyngeal pH monitoring Infection, cancer, allergies Omeprazole 40 mg bd 8 Significant reduction in mean composite symptom score No
El-Serag (2001) 22 Symptoms for ≥3 wks and laryngoscopic signs of LPR Infection, cancer, allergies Lansoprazole 30 mg bd 12 Complete symptom resolution Yes?
Eherer (2003) 21 Hoarseness for ≥8 wks and laryngoscopic signs of LPR Smokers Pantoprazole 40 mg bd 12 Significant reduction in mean composite symptom score No
Steward (2004) 42 Symptoms for ≥4 wks and laryngoscopic signs of LPR Current or recent (within 1 mth) use of H2RA or PPI Rabeprazole 20 mg bd 8 Significant improvement in mean composite symptom score No
Wo (2006) 39 Symptoms and laryngoscopic signs of LPR. Abnormal triple- sensor pH monitoring Previous treatment of GERD Pantoprazole 20 mg od 12 Patient reported global adequate relief of symptoms No
Vaezi (2006) 146 Laryngeal symptoms for ≥12 wks and laryngoscopic signs of LPR Moderate to severe heartburn in 3 weeks prior to enrollment Esomeprazole 40 mg bd 16 Resolution of most bothersome symptom No

Abbreviations: GERD, gastro-oesophageal reflux disease; LPR, laryngopharyngeal reflux; PPI, proton pump inhibitor.